Teladoc Health, Inc. (NYSE:TDOC) Holdings Boosted by Centiva Capital LP

Centiva Capital LP increased its stake in shares of Teladoc Health, Inc. (NYSE:TDOC - Free Report) by 679.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 244,615 shares of the health services provider's stock after buying an additional 213,234 shares during the period. Centiva Capital LP owned about 0.14% of Teladoc Health worth $2,224,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Brevan Howard Capital Management LP raised its position in shares of Teladoc Health by 49.8% during the 4th quarter. Brevan Howard Capital Management LP now owns 228,351 shares of the health services provider's stock worth $2,076,000 after purchasing an additional 75,961 shares during the last quarter. Bridgefront Capital LLC acquired a new stake in shares of Teladoc Health during the fourth quarter valued at $130,000. Bayesian Capital Management LP purchased a new stake in Teladoc Health during the 4th quarter worth about $170,000. Algert Global LLC acquired a new position in Teladoc Health in the 4th quarter valued at about $313,000. Finally, Maple Rock Capital Partners Inc. boosted its stake in shares of Teladoc Health by 189.5% during the 4th quarter. Maple Rock Capital Partners Inc. now owns 3,561,000 shares of the health services provider's stock worth $32,369,000 after purchasing an additional 2,331,000 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Stock Up 3.2%

Shares of NYSE:TDOC traded up $0.23 during trading on Monday, hitting $7.34. The company's stock had a trading volume of 1,953,095 shares, compared to its average volume of 6,235,362. The company has a market capitalization of $1.29 billion, a PE ratio of -1.27 and a beta of 1.82. Teladoc Health, Inc. has a fifty-two week low of $6.35 and a fifty-two week high of $15.21. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. The stock's 50-day moving average price is $7.75 and its two-hundred day moving average price is $9.42.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.07). Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The company had revenue of $640.49 million for the quarter, compared to analyst estimates of $639.44 million. As a group, sell-side analysts expect that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Insider Activity at Teladoc Health

In other news, insider Adam C. Vandervoort sold 11,011 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $8.42, for a total value of $92,712.62. Following the completion of the sale, the insider now directly owns 64,308 shares in the company, valued at approximately $541,473.36. The trade was a 14.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.58% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TDOC shares. Stifel Nicolaus decreased their target price on shares of Teladoc Health from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Thursday, May 1st. Royal Bank of Canada upped their target price on Teladoc Health from $11.00 to $12.00 and gave the company an "outperform" rating in a research note on Friday, January 24th. Bank of America decreased their price target on Teladoc Health from $9.50 to $8.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Jefferies Financial Group lowered their price target on Teladoc Health from $10.00 to $8.00 and set a "hold" rating for the company in a report on Monday, April 21st. Finally, Canaccord Genuity Group cut their price objective on shares of Teladoc Health from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Twelve equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $9.71.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.